For millions of older Americans living with atrial fibrillation (AFib), the 2026 Medicare Part D premium cap has brought a measure of financial relief. Direct oral anticoagulants (DOACs) like apixaban, which once cost hundreds of dollars a month out of pocket, now fall under a roughly $2,000 annual maximum. But the cap, while substantial, does not erase all cost barriers—and some patients remain largely unaffected by it. As clinicians and policymakers examine the early impact, a more nuanced picture emerges: the cap helps many, but the structure of insurance design, formulary placement, and racial disparities in prescribing continue to shape who actually benefits.

Part D Cap Cuts AFib Drug Copays by Hundreds of Dollars—But Not for Everyone

Before the cap, a Medicare beneficiary taking apixaban could face monthly copays of $500 or more during the coverage gap, often called the “donut hole.” For a full year, that meant spending well over $5,000 before catastrophic coverage kicked in. Under the 2026 reform, out-of-pocket costs for any Part D drug are capped at roughly $2,000 annually. For apixaban, that translates to copays of around $50–$100 per month, depending on the plan.

The cap applies to all Part D plans, but beneficiaries still must meet their deductible before the cap takes full effect. In 2026, the standard deductible is about $545. During that period, patients pay full price for brand-name DOACs. Once the deductible is met, cost-sharing drops to a fixed copay or coinsurance, typically 25% of the drug’s price, until the $2,000 cap is reached.

For lower-income beneficiaries, the Extra Help program—which covers most Part D costs—has existed for years, yet enrollment remains stubbornly low. Some estimates suggest that nearly 2 million eligible Medicare beneficiaries have not signed up, often because they are unaware of the program or find the application process daunting. The cap does not automatically enroll them, so these patients may still struggle with costs that others no longer face.

Meanwhile, patients on brand-name DOACs that lack generic equivalents—such as edoxaban—may still face higher coinsurance until they hit the cap. The cap is an annual ceiling, not a per-prescription limit, so the burden is front-loaded. For patients who fill their prescription early in the year, the first few months can still be expensive.

Consider a typical patient in a high-deductible Medicare Advantage plan: they might pay the full negotiated price for apixaban—around $550 per month—until they meet a $1,500 deductible, then continue with 25% coinsurance until the $2,000 cap. That means spending roughly $2,000 in the first few months, which for a retiree on a fixed income can be a significant shock. By contrast, a patient in a low-deductible plan might pay a flat $50 copay from the start, reaching the cap only after many months. The cap standardizes the maximum, but the path to get there varies widely.

The Cap Leaves a Gap for Patients on Older Warfarin Regimens

Warfarin, the decades-old anticoagulant, costs pennies per pill—typically less than $10 a month without insurance. But the drug is not the only cost. Patients on warfarin require regular blood tests to measure the international normalized ratio (INR), and those tests are covered under Medicare Part B, not Part D. The Part D cap does nothing to address Part B expenses.

INR monitoring visits can cost anywhere from $20 to $50 or more per test, depending on the facility and whether the patient has supplemental insurance. For patients who need weekly testing—common after dose changes or when starting new medications—the cumulative cost can exceed several hundred dollars a year. The cap does not apply.

Some patients, such as those with mechanical heart valves or antiphospholipid syndrome, cannot use DOACs and must remain on warfarin. For them, the cap offers no financial benefit. A cardiologist at a large academic center noted in a recent interview that these patients often express frustration that the “big news” about drug costs seems to bypass them entirely.

Anticoagulation clinics, which manage warfarin dosing and INR testing, are also Part B services. While some plans offer reduced copays for in-network labs, the variability is high. Patients in rural areas may have to travel long distances to reach a clinic, adding indirect costs that the cap cannot touch.

Take a 78-year-old woman in rural Montana with a mechanical mitral valve: she must take warfarin for life and requires INR checks every two weeks. Each test costs her $35 after Medicare Part B coverage, plus she drives 60 miles round trip to the nearest clinic. That adds up to roughly $900 a year in direct medical costs and hundreds more in travel expenses. The Part D cap does nothing for her. She is not alone—an estimated 1 million Medicare beneficiaries remain on warfarin, and many face similar burdens.

Insurance Design Still Shapes Which Drug a Patient Actually Gets

Even with the cap, the specific DOAC a patient receives depends heavily on their Part D plan’s formulary. Apixaban and rivaroxaban are typically placed on tier 3 or tier 4, meaning higher cost-sharing before the cap is reached. Edoxaban, a newer DOAC, often requires prior authorization, adding a paperwork hurdle for prescribers.

Step therapy is another barrier. Some plans require patients to try warfarin first before covering rivaroxaban. For a patient with AFib and no contraindication to warfarin, this can mean weeks or months on an older drug before switching. The delay may increase the risk of stroke during the trial period, especially if the patient has difficulty maintaining a therapeutic INR.

Patients enrolled in high-deductible health plans—a growing share of Medicare Advantage enrollees—pay the full price of their DOAC until the deductible is met. For a drug that costs $500–$600 per month, that can mean $1,500–$2,000 out of pocket before the cap even starts. The cap then applies, but the upfront cost remains a barrier for many.

In a recent survey of cardiologists, nearly half reported spending at least 10 minutes per visit on insurance-related appeals for anticoagulants. That time could be spent on clinical decision-making, but the administrative burden persists. As one clinician put it, “The cap helps, but it doesn’t fix the maze.”

Consider a patient whose plan places apixaban on tier 4 with a 30% coinsurance, while rivaroxaban is on tier 3 with a 25% coinsurance. The clinician may prefer apixaban due to once-daily dosing or lower bleeding risk, but the patient might push for the cheaper option. The cap ultimately limits total spending, but the choice between drugs can still be influenced by cost differences before the cap is reached. This creates a tension between clinical judgment and financial reality.

Racial and Ethnic Disparities Persist Despite Premium Cap

Research consistently shows that Black patients with AFib are less likely to be prescribed DOACs than white patients, even after adjusting for clinical factors. Instead, they are more often maintained on warfarin, which requires more frequent monitoring and has a higher risk of bleeding if INR is not well controlled. The cap does not address this prescribing gap.

Hispanic patients also face disparities. A 2024 analysis of Medicare claims found that Hispanic beneficiaries had 20% lower odds of receiving a DOAC compared with non-Hispanic white beneficiaries. Language barriers and limited health literacy may contribute: drug information materials are often available only in English, and discussions about the risks and benefits of different anticoagulants may not be fully accessible.

The cap itself is colorblind—it applies equally to all beneficiaries—but the underlying patterns of unequal prescribing remain. A policy that lowers costs cannot fix a system where clinicians inadvertently steer minority patients toward older, less convenient therapies. Some experts argue that implicit bias and differences in care settings play a role, as Black and Hispanic patients are more likely to receive care in under-resourced clinics where DOAC prescribing may be less routine.

Efforts to standardize anticoagulant prescribing through clinical decision support tools have shown promise but are not yet widespread. Until they are, the cap will leave untouched the deeper inequities in who gets the newest—and often safest—drugs.

For example, a 2025 study found that among Medicare beneficiaries with AFib, Black patients were 30% less likely to receive a DOAC prescription within 90 days of diagnosis compared to white patients, even when seen at the same hospital system. The cap does not address the underlying reasons—which may include differences in how risk scores are applied, patient-clinician communication, or trust in the healthcare system. Without targeted interventions, the gap persists.

What the Evidence Says About Adherence and Outcomes Under the Cap

Early data from Medicare claims suggest that the cap has led to a roughly 15% increase in DOAC prescription fills in the first quarter of 2026 compared with the same period in 2025. That is a meaningful bump, but it does not mean all patients are taking their medications as prescribed.

Adherence to DOACs remains suboptimal. Studies from before the cap found that about 40% of patients discontinue their DOAC within the first year, often due to cost or side effects. Preliminary post-cap data show a slight improvement, with discontinuation rates dropping to around 35%, but that still leaves more than a third of patients stopping therapy early.

Stroke and bleeding rates have not changed significantly in the first six months after the cap’s implementation, according to a Medicare analysis presented at a recent cardiology meeting. That is not entirely surprising: adherence improvements take time to translate into clinical outcomes, and the follow-up period is still short. Researchers caution that longer-term data are needed to see if the cap reduces strokes or hospitalizations.

One potential concern is that patients who now face lower costs may be more likely to start a DOAC but then stop if they experience minor bleeding or other side effects. The cap does not include a mechanism for counseling or follow-up, so patients may still discontinue therapy without consulting their clinician. The net effect on cardiovascular outcomes remains an open question.

Consider a patient who starts apixaban in January, reaches the cap by March after paying $2,000 out of pocket, and then experiences easy bruising in April. Without a copayment to remind them of the medication's value, they might stop taking it without calling their doctor. A study of medication adherence suggests that even small copayments can improve persistence, as they signal the drug's importance. The cap, by reducing ongoing costs, might inadvertently weaken that signal. This is a trade-off that policymakers need to monitor.

Policy Fixes Beyond the Cap Could Narrow Remaining Gaps

Several policy proposals could build on the cap to address its limitations. Eliminating prior authorization for all DOACs in Part D would remove a key administrative barrier. A 2025 study estimated that such a move could increase DOAC use by roughly 10% among patients who currently face step therapy or prior auth hurdles.

Expanding Extra Help enrollment through automatic data matching—similar to how the Supplemental Nutrition Assistance Program (SNAP) uses income data to enroll eligible individuals—could reach the millions of beneficiaries who currently miss out. Some states have piloted such programs with success, but a national rollout has not been adopted.

Covering INR monitoring under Part D as part of medication therapy management would close the gap for warfarin users. This would require a legislative change, as Part D currently covers only drugs, not lab tests. But advocates argue that integrating monitoring into drug coverage would simplify care and reduce costs for the roughly 1 million Medicare beneficiaries still on warfarin.

A more ambitious proposal is the creation of a federal formulary for anticoagulants, which would standardize coverage across all Part D plans. Such a formulary could mandate that all four DOACs be available without prior authorization or step therapy, ensuring that patients can access the drug their clinician deems best. The idea has support from some patient advocacy groups but faces opposition from insurers who value formulary flexibility.

Another option is to cap out-of-pocket costs for Part B services as well, particularly for lab tests and monitoring. While not directly related to drug coverage, such a cap would help warfarin users. A combined Part B and Part D out-of-pocket maximum has been discussed in policy circles but has not gained traction due to cost concerns. The trade-off is that it would increase premiums for all beneficiaries, which may be politically challenging.

For Now, Patients and Clinicians Must Navigate a Patchwork System

Until further reforms are enacted, the day-to-day reality for patients and clinicians is one of persistent complexity. Cardiologists report that they still spend a notable portion of each visit discussing insurance appeals or helping patients compare plans. The Medicare Plan Finder tool, updated for 2026, now includes clearer cost estimates for specific drugs, but the interface remains cumbersome for many older adults.

Nonprofit patient assistance programs, such as those run by the American Heart Association and individual drug manufacturers, can help cover copays for patients who fall through the cracks. But these programs vary by drug and by income level, and they often require separate applications that patients may not know about or have time to complete.

Shared decision-making about cost is now an essential part of the clinic visit. Clinicians increasingly ask patients about their insurance plan and out-of-pocket limits before prescribing a DOAC. Some practices have hired dedicated staff to handle prior authorizations and copay assistance, but that is a luxury not available in every setting.

The cap is a significant step forward—it has already lowered costs for hundreds of thousands of Medicare beneficiaries with AFib. But it is not a silver bullet. Until the remaining gaps in formulary design, monitoring coverage, and prescribing equity are addressed, the promise of affordable anticoagulation will remain out of reach for some of the patients who need it most.

This article is for informational purposes only and does not constitute medical advice. Patients should consult their healthcare provider for personalized treatment decisions.